First-Line Third-Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

ABSTRACT: Third-generation (third-gen) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the management of advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, a head-to-head comparison of efficacy and safety among third-gen EGFR TKIs is lacking. Seven randomized controlled trials with 3012 patients were included. All third-gen TKIs significantly prolonged progression-free survival (PFS) compared to first-generation (first-gen) TKIs, with no significant differences in PFS or objective response rate among the third-gen TKIs. Furmonertinib ranked highest for PFS (HR, 0.82; 95% credible intervals [CrI], 0.72-0.94). Aumolertinib demonstrated the best intracranial control (HR, 0.74; 95% CrI, 0.63-0.89). Osimertinib (HR, 0.90; 95% CrI, 0.83-0.99) a

SUBMITTER: Du W 

PROVIDER: S-EPMC12592680 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature